The document discusses the use of ELISPOT assays to monitor cell-mediated immunity during vaccine development. It describes the advantages of ELISPOT assays, including their high sensitivity to detect low frequency T-cell responses directly ex vivo. The presentation outlines strategies for standardizing ELISPOT assays across clinical sites and laboratories to generate robust immune monitoring data for vaccine trials. Harmonizing sample collection, assay methods, and data analysis can facilitate the broad implementation of ELISPOT-based immune monitoring in regulated clinical research environments.
Scientific Comprehension of Cell Line Development Strategy Based on the CHOZN...Merck Life Sciences
Watch the presentation of this webinar here: https://bit.ly/3kO8Yku
Stable outcomes in cell line development rely heavily on the optimization of process factors in the initiation phase. This webinar will help give you an understanding of the scientific background of these factors so you can develop a flexible strategy that is appropriate for your environment.
Stable cell line development (CLD) for recombinant glycan proteins – despite its 40-year history - still suffers due to unexpected and vulnerable outputs caused by the influence of unpredictable traits of the base host cell line. However, recently - through the CHOZN-GS system - we observe better CLD performance than other CHO systems in terms of time, cost, titer, stability, and scale-up, due in part to its robust genetic stability. In particular, we find that optimization of key CLD process factors at an early stage have a large impact on the final outcome. In this talk, we will share how CLD strategies can be flexibly optimized under given conditions through an understanding of the scientific context.
In this webinar, you will learn:
• Screening & selection strategy of "easy to express Fc-fusion protein" structure
• Optimization strategy of major CLD process factor
Presented by: Dr. Young Min Oh
Senior Director, GI Innovation
Pegs Europe 2015 Protein & Antibody Engineering SummitNicole Proulx
PEGS Europe is the largest European event covering all aspects of protein and antibody engineering. With three consecutive years of 35% growth in attendance, and another year of expanded program coverage, this year’s event will feature:
700 attendees
175 technical presentations
125 scientific posters
Dedicated networking opportunities
Exclusive exhibit & poster viewing hours
Interactive roundtable, breakout & panel discussions
Large-scale Production of Stem Cells Utilizing MicrocarriersZohaib HUSSAIN
Large-scale Production of Stem Cells Utilizing MicrocarriersLarge-scale Production of Stem Cells Utilizing MicrocarriersLarge-scale Production of Stem Cells Utilizing MicrocarriersLarge-scale Production of Stem Cells Utilizing MicrocarriersLarge-scale Production of Stem Cells Utilizing MicrocarriersLarge-scale Production of Stem Cells Utilizing MicrocarriersLarge-scale Production of Stem Cells Utilizing MicrocarriersLarge-scale Production of Stem Cells Utilizing MicrocarriersLarge-scale Production of Stem Cells Utilizing MicrocarriersLarge-scale Production of Stem Cells Utilizing Microcarriers
Scientific Comprehension of Cell Line Development Strategy Based on the CHOZN...Merck Life Sciences
Watch the presentation of this webinar here: https://bit.ly/3kO8Yku
Stable outcomes in cell line development rely heavily on the optimization of process factors in the initiation phase. This webinar will help give you an understanding of the scientific background of these factors so you can develop a flexible strategy that is appropriate for your environment.
Stable cell line development (CLD) for recombinant glycan proteins – despite its 40-year history - still suffers due to unexpected and vulnerable outputs caused by the influence of unpredictable traits of the base host cell line. However, recently - through the CHOZN-GS system - we observe better CLD performance than other CHO systems in terms of time, cost, titer, stability, and scale-up, due in part to its robust genetic stability. In particular, we find that optimization of key CLD process factors at an early stage have a large impact on the final outcome. In this talk, we will share how CLD strategies can be flexibly optimized under given conditions through an understanding of the scientific context.
In this webinar, you will learn:
• Screening & selection strategy of "easy to express Fc-fusion protein" structure
• Optimization strategy of major CLD process factor
Presented by: Dr. Young Min Oh
Senior Director, GI Innovation
Pegs Europe 2015 Protein & Antibody Engineering SummitNicole Proulx
PEGS Europe is the largest European event covering all aspects of protein and antibody engineering. With three consecutive years of 35% growth in attendance, and another year of expanded program coverage, this year’s event will feature:
700 attendees
175 technical presentations
125 scientific posters
Dedicated networking opportunities
Exclusive exhibit & poster viewing hours
Interactive roundtable, breakout & panel discussions
Large-scale Production of Stem Cells Utilizing MicrocarriersZohaib HUSSAIN
Large-scale Production of Stem Cells Utilizing MicrocarriersLarge-scale Production of Stem Cells Utilizing MicrocarriersLarge-scale Production of Stem Cells Utilizing MicrocarriersLarge-scale Production of Stem Cells Utilizing MicrocarriersLarge-scale Production of Stem Cells Utilizing MicrocarriersLarge-scale Production of Stem Cells Utilizing MicrocarriersLarge-scale Production of Stem Cells Utilizing MicrocarriersLarge-scale Production of Stem Cells Utilizing MicrocarriersLarge-scale Production of Stem Cells Utilizing MicrocarriersLarge-scale Production of Stem Cells Utilizing Microcarriers
What process is used to obtain cells from bone marrow and normal peripheral blood?
What is the best cell counting and viability method for primary cells?
AllCells, your primary cells research partner, and Nexcelom Bioscience, your cell counting experts, have joined together in an exclusive collaboration to host a free webinar to help educate researchers and present data from their own experiences.
ELISA Vs ELISPOT - Principle, Procedure, Advantagesajithnandanam
The Enzyme Linked Immunospot (ELISPOT) technique was developed by Cecil Czerkinskdy in 1983. ELISPOT is used for the detection of secreted proteins, such as cytokines and growth factors. ELISPOT is primarily used in immunology research in the following areas:
Finalità didattiche del mio lavoro multimediale fattibile in un’aula provvista almeno di LIM.
Ho realizzato un power point animato da inserire nella pag.79 dell’ebook “Biochimica” di Niccòlo Taddei . La finalità principale è favorire negli alunni il passaggio da una conoscenza tacita a una consapevole.
Nella prima slide ho messo in evidenza l’argomento da trattare.
Nella seconda e terza slide stimolo gli alunni col problem solving invitandoli a cercare soluzione in rete (gli alunni possono fare ciò sia in aula se la classe è di tipo 2.0, oppure a casa comunicando con i compagni e il docente tramite i social network) ed a creare oggetti didattici con l’ausilio di programmi indicati nelle slide; propongo inoltre attività per la rielaborazione di conoscenze.
Nella quarta slide dopo aver guidato gli alunni nell’analisi dello schema della glicolisi riportato nel testo suddetto, propongo loro un approfondimento sulla stessa tramite una versione in musica rap inglese della glicolisi.
Nelle slide successive col fine di consolidare le competenze propongo delle attività che gli alunni possono svolgere sia singolarmente sia organizzati in squadre.
The Life-Changing Impact of AI in HealthcareKalin Hitrov
For IT Leaders in the healthcare and pharmaceutical industries looking to understand the impact of AI on their industries and how to overcome the ethical and efficiency challenges that come with its use.
To learn more visit:
https://insidescientific.com/webinar/cutting-edge-conversations-discovering-new-innovations-in-oncology/
Starting off the conversation, Dr. David Bunka will present specific case studies for prostate cancer, multiple myeloma and chronic myelomonocytic leukaemia, highlighting the ability of Optimer technology to deliver novel targeted therapeutics for cancer treatment. Optimer binders are small, highly target specific oligonucleotide-based affinity binders. The Optimer platform offers the ability to develop specific binders targeted to a specific biomarker or to an oncological cell phenotype without the need for known biomarkers. Optimer therapeutics are enabling new strategies in cancer treatment, including the targeted delivery of diverse payloads to cancer cells for precision chemotherapy, or gene therapy approaches.
Dr. Cathie Miller will discuss how archived tissues contain valuable information for clinical research. For over thirty years, BioIVT has worked to expand the characterization of their archived tissues. BioIVT offers complete NGS project management that ensures success. In this presentation, Dr. Miller will review BioIVT’s comprehensive process, their strengths in sample collection through library prep, their in-house and validated partnership capabilities and how BioIVT elevates science.
Finally, Henry Sebesta will introduce KromaTiD’s proprietary technology, Directional Genomic Hybridization™, as an analytical solution for gene & cell therapy oncology treatments. Specifically, Mr. Sebesta will be addressing what Directional Genomic Hybridization is, how it works, and how it can be used to monitor highly important clinical safety metrics including therapeutic vector integration, and genome wide structural rearrangement events.
This intro is geared towards interested novices who wish to find a resource that can serve as a starting point for further self-study. This is not meant to replace a doctor's advice. Please approach a medical professional for any health condition.
What process is used to obtain cells from bone marrow and normal peripheral blood?
What is the best cell counting and viability method for primary cells?
AllCells, your primary cells research partner, and Nexcelom Bioscience, your cell counting experts, have joined together in an exclusive collaboration to host a free webinar to help educate researchers and present data from their own experiences.
ELISA Vs ELISPOT - Principle, Procedure, Advantagesajithnandanam
The Enzyme Linked Immunospot (ELISPOT) technique was developed by Cecil Czerkinskdy in 1983. ELISPOT is used for the detection of secreted proteins, such as cytokines and growth factors. ELISPOT is primarily used in immunology research in the following areas:
Finalità didattiche del mio lavoro multimediale fattibile in un’aula provvista almeno di LIM.
Ho realizzato un power point animato da inserire nella pag.79 dell’ebook “Biochimica” di Niccòlo Taddei . La finalità principale è favorire negli alunni il passaggio da una conoscenza tacita a una consapevole.
Nella prima slide ho messo in evidenza l’argomento da trattare.
Nella seconda e terza slide stimolo gli alunni col problem solving invitandoli a cercare soluzione in rete (gli alunni possono fare ciò sia in aula se la classe è di tipo 2.0, oppure a casa comunicando con i compagni e il docente tramite i social network) ed a creare oggetti didattici con l’ausilio di programmi indicati nelle slide; propongo inoltre attività per la rielaborazione di conoscenze.
Nella quarta slide dopo aver guidato gli alunni nell’analisi dello schema della glicolisi riportato nel testo suddetto, propongo loro un approfondimento sulla stessa tramite una versione in musica rap inglese della glicolisi.
Nelle slide successive col fine di consolidare le competenze propongo delle attività che gli alunni possono svolgere sia singolarmente sia organizzati in squadre.
The Life-Changing Impact of AI in HealthcareKalin Hitrov
For IT Leaders in the healthcare and pharmaceutical industries looking to understand the impact of AI on their industries and how to overcome the ethical and efficiency challenges that come with its use.
To learn more visit:
https://insidescientific.com/webinar/cutting-edge-conversations-discovering-new-innovations-in-oncology/
Starting off the conversation, Dr. David Bunka will present specific case studies for prostate cancer, multiple myeloma and chronic myelomonocytic leukaemia, highlighting the ability of Optimer technology to deliver novel targeted therapeutics for cancer treatment. Optimer binders are small, highly target specific oligonucleotide-based affinity binders. The Optimer platform offers the ability to develop specific binders targeted to a specific biomarker or to an oncological cell phenotype without the need for known biomarkers. Optimer therapeutics are enabling new strategies in cancer treatment, including the targeted delivery of diverse payloads to cancer cells for precision chemotherapy, or gene therapy approaches.
Dr. Cathie Miller will discuss how archived tissues contain valuable information for clinical research. For over thirty years, BioIVT has worked to expand the characterization of their archived tissues. BioIVT offers complete NGS project management that ensures success. In this presentation, Dr. Miller will review BioIVT’s comprehensive process, their strengths in sample collection through library prep, their in-house and validated partnership capabilities and how BioIVT elevates science.
Finally, Henry Sebesta will introduce KromaTiD’s proprietary technology, Directional Genomic Hybridization™, as an analytical solution for gene & cell therapy oncology treatments. Specifically, Mr. Sebesta will be addressing what Directional Genomic Hybridization is, how it works, and how it can be used to monitor highly important clinical safety metrics including therapeutic vector integration, and genome wide structural rearrangement events.
This intro is geared towards interested novices who wish to find a resource that can serve as a starting point for further self-study. This is not meant to replace a doctor's advice. Please approach a medical professional for any health condition.